• Molecular NameNilutamide
  • SynonymNA
  • Weight317.223
  • Drugbank_IDDB00665
  • ACS_NO63612-50-0
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.77
  • pkaN/A
  • LogD (pH=7, predicted)1.77
  • Solubility (experiment)1 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.67
  • LogSw (predicted, AB/LogsW2.0)0.71
  • Sw (mg/ml) (predicted, ACD/Labs)0.06
  • No.of HBond Donors1
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds3
  • TPSA98.24
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antiandrogen medication used in the treatment of advanced stage prostate cancer.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNilutamide is extensively metabolized and less than 2% of the drug is excreted unchanged in urine after 5 days.
  • Half life7 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include dizziness, general discomfort, headache, nausea, and vomiting.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A